Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$0.94
+0.1%
$1.19
$0.66
$4.20
$107.30M2.242.04 million shs963,447 shs
Immuneering Corporation stock logo
IMRX
Immuneering
$3.25
+1.2%
$3.28
$1.00
$4.69
$116.97M0.371.25 million shs447,126 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$0.77
+8.2%
$0.92
$0.66
$3.02
$34.52M2.85584,527 shs1.60 million shs
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$15.44
+6.3%
$11.20
$6.53
$26.40
$135.10M2.997,879 shs82,913 shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
+1.55%-11.73%-18.63%-6.43%-72.23%
Immuneering Corporation stock logo
IMRX
Immuneering
-1.23%-6.41%-27.38%+150.78%+194.50%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+0.45%+0.06%-36.80%-23.89%-39.47%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
+2.25%-1.69%+15.59%+97.15%-19.86%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
4.0208 of 5 stars
3.12.00.04.72.42.50.6
Immuneering Corporation stock logo
IMRX
Immuneering
3.5716 of 5 stars
3.33.00.00.03.25.00.6
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.242 of 5 stars
3.53.00.00.02.21.70.0
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3.3203 of 5 stars
2.91.00.04.63.10.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
2.13
Hold$3.83309.41% Upside
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25307.69% Upside
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.001,064.29% Upside
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
1.75
Reduce$73.67377.12% Upside

Current Analyst Ratings Breakdown

Latest ITRM, FATE, MCRB, and IMRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/12/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.00
5/14/2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
$13.63M7.87N/AN/A$2.80 per share0.33
Immuneering Corporation stock logo
IMRX
Immuneering
$320K365.52N/AN/A$1.33 per share2.44
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$126.32M1.07N/AN/A$1.61 per share9.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$186.26M-$1.49N/AN/AN/A-1,318.93%-47.17%-34.60%8/12/2025 (Estimated)
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/12/2025 (Estimated)
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.85N/AN/AN/AN/A-65.01%N/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%N/A

Latest ITRM, FATE, MCRB, and IMRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.34-$0.29+$0.05-$0.29$1.16 millionN/A
8/12/2025Q2 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.40N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A
8/5/2025Q2 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.13-$0.16-$0.03-$0.16N/AN/A
5/13/2025Q1 2025
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
N/A
8.81
8.81
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
2.69
2.52
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
N/A
1.57
1.57

Institutional Ownership

CompanyInstitutional Ownership
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
97.54%
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
59.34%

Insider Ownership

CompanyInsider Ownership
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
5.51%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
2.40%
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fate Therapeutics, Inc. stock logo
FATE
Fate Therapeutics
550114.60 million108.29 millionOptionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1044.66 million43.59 millionNot Optionable
Seres Therapeutics, Inc. stock logo
MCRB
Seres Therapeutics
3308.75 million8.34 millionOptionable

Recent News About These Companies

Seres Therapeutics Reports Q2 Results and Leadership Change
Seres (MCRB) Q2 Loss Narrows 34%
Seres Therapeutics trading resumes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Fate Therapeutics stock logo

Fate Therapeutics NASDAQ:FATE

$0.94 +0.00 (+0.06%)
Closing price 04:00 PM Eastern
Extended Trading
$0.95 +0.01 (+1.25%)
As of 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$3.25 +0.04 (+1.25%)
Closing price 04:00 PM Eastern
Extended Trading
$3.26 +0.01 (+0.31%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$0.77 +0.06 (+8.23%)
Closing price 04:00 PM Eastern
Extended Trading
$0.78 +0.01 (+1.03%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Seres Therapeutics stock logo

Seres Therapeutics NASDAQ:MCRB

$15.44 +0.91 (+6.26%)
Closing price 04:00 PM Eastern
Extended Trading
$15.07 -0.37 (-2.40%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.